Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet

by

  1. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet
  2. Merck clashes with AstraZeneca in biliary tract cancer FiercePharma
  3. AACR 2023 – more hope for Moderna’s neoantigen immunotherapy Evaluate Pharma
  4. Pembrolizumab Plus Gemcitabine/Cisplatin Provided Significant Improvement in OS in Advanced Biliary Tract Cancer Pharmacy Times
  5. Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano Yahoo Finance
  6. View Full Coverage on Google News

Read original article here

Leave a Comment